Table 2.

Patient treatment characteristics (self‐reported)

	All patients (n = 289)
	n (%)
Treatment status
No treatment decision made	13 (4.5)
Decision made, not yet started treatment	74 (25.6)
Currently on treatment	119 (41.2)
Completed treatment	83 (28.7)
	Patients who have started treatment (n = 202)
Time since initiation of first‐line HL treatment (years)
Mean (SD)	1.2 (0.7)
Median (IQR)	1 (0‐2)
	Patients who have completed treatment (n = 83)
Response to front‐line
Complete response/in remission	62 (74.7)
Relapsed	23 (27.7)
Not a complete response/not in remission	15 (18.1)
Unknown	6 (7.2)
Treatment following front‐line
Radiotherapy	23 (27.7)
Chemotherapy	25 (30.1)
Immunotherapy/targeted therapy	10 (12.0)
Stem cell transplant	1 (1.2)
Additional treatment was unknown	7 (8.4)
No additional treatment	17 (20.5)
Recently experienced health issues
Lung damage	11 (13.3)
Heart damage	2 (2.4)
Another cancer	42 (50.6)
Peripheral neuropathy	4 (4.8)
None	32 (38.6)